Aron R. English Sells 1,139,504 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock

Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report) major shareholder Aron R. English sold 1,139,504 shares of the stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $6.50, for a total transaction of $7,406,776.00. Following the completion of the transaction, the insider now owns 414,599 shares of the company's stock, valued at approximately $2,694,893.50. The trade was a 73.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Lifecore Biomedical Stock Down 3.5%

NASDAQ:LFCR traded down $0.24 on Friday, reaching $6.61. 179,835 shares of the stock traded hands, compared to its average volume of 240,935. The company has a market capitalization of $244.74 million, a price-to-earnings ratio of -11.80 and a beta of 0.65. The company has a current ratio of 2.32, a quick ratio of 1.21 and a debt-to-equity ratio of 9.21. Lifecore Biomedical, Inc. has a 12 month low of $3.68 and a 12 month high of $7.99. The company's fifty day simple moving average is $6.52 and its 200 day simple moving average is $6.57.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last announced its quarterly earnings results on Thursday, April 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The company had revenue of $35.15 million for the quarter, compared to analysts' expectations of $33.23 million. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. Equities analysts predict that Lifecore Biomedical, Inc. will post -0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, William Blair initiated coverage on shares of Lifecore Biomedical in a research note on Wednesday, May 21st. They set an "outperform" rating for the company.

Institutional Trading of Lifecore Biomedical

A number of institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Lifecore Biomedical by 14.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company's stock valued at $104,000 after acquiring an additional 1,886 shares during the last quarter. Bridgeway Capital Management LLC boosted its holdings in shares of Lifecore Biomedical by 2.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 78,800 shares of the company's stock valued at $585,000 after acquiring an additional 1,900 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Lifecore Biomedical by 29.0% during the 4th quarter. Wells Fargo & Company MN now owns 13,381 shares of the company's stock valued at $99,000 after acquiring an additional 3,012 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Lifecore Biomedical by 3.8% during the 1st quarter. Bank of New York Mellon Corp now owns 83,663 shares of the company's stock valued at $589,000 after acquiring an additional 3,091 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Lifecore Biomedical by 1,839.7% during the 1st quarter. GAMMA Investing LLC now owns 3,569 shares of the company's stock valued at $25,000 after acquiring an additional 3,385 shares during the last quarter. Hedge funds and other institutional investors own 83.36% of the company's stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.